title: [Bone hyperresorption in bone metastases].
abstract: MECHANISMS OF BONE LOSS: In patients with bone metastases, bone loss is the consequence of a dissociated process combining excessive bone resorption and inhibited bone formation. This destructive process occurs in response to soluble factors secreted by metastatic cells (PTH-rP, cytokines) which activate osteoclasts. These cells also secrete proteases (cathepsin K, metalloprotease MMP-9) which degrade the bone's collagen network. Excessive bone resorption is also favored by direct interaction between the metastatic cells and stromal cells in the bone marrow in response to the activation of membrane receptors (integrins a4 beta 1 and a4 beta 7). Finally, metastatic cells secrete non-identified soluble factors capable of inhibiting osteoblast proliferation in vitro. EFFECT OF BONE LOSS ON THE METASTASIS: Bone is a major reservoir of growth factors (mainly TGF beta and IGF-1). Positive feedback mechanism operates at the site of osteolysis where TGF beta released by bone tissue induces a paracrine stimulation of PTH-rP production by metastatic cells. IGF-1 released by the bone favors grow of metastatic cells present in the marrow. In addition, IGF-1 as well as collagen proteolytic fragments may stimulate recruitment of new metastatic cells at the site of the bone metastasis. This creates a vicious circle of mutual stimulation between bone destruction and tumor proliferation.
authors.affiliation: INSERM U.403, Faculté de Médecine Laënnec, Lyon. clezardin@lyon151.inserm.fr
authors.forename: P
authors.initials: P
authors.lastname: Clézardin
mesh_terms: D000818:Animals; D001853:Bone Marrow / Q000473:pathology; D001857:Bone Matrix / Q000473:pathology; D001859:Bone Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology* / Q000556:secondary*; D001862:Bone Resorption / Q000473:pathology / Q000503:physiopathology / Q000517:prevention & control; D001943:Breast Neoplasms / Q000473:pathology; D016207:Cytokines / Q000502:physiology; D004164:Diphosphonates / Q000627:therapeutic use; D005260:Female; D006801:Humans; D015674:Mammary Neoplasms, Animal / Q000473:pathology; D008545:Melanoma / Q000473:pathology; D051379:Mice; D009101:Multiple Myeloma / Q000473:pathology; D009363:Neoplasm Proteins / Q000502:physiology; D010006:Osteoblasts / Q000473:pathology; D010010:Osteoclasts / Q000473:pathology; D010014:Osteolysis / Q000473:pathology / Q000503:physiopathology; D010281:Parathyroid Hormone / Q000502:physiology; D044162:Parathyroid Hormone-Related Protein; D011506:Proteins / Q000502:physiology; D017154:Stromal Cells / Q000473:pathology; D014407:Tumor Cells, Cultured / Q000473:pathology
chemical_list: D016207:Cytokines; D004164:Diphosphonates; D009363:Neoplasm Proteins; C470121:PTHLH protein, human; D010281:Parathyroid Hormone; D044162:Parathyroid Hormone-Related Protein; D011506:Proteins